Abstract
Background: Gain-of-function K+ channel mutations cause familial atrial fibrillation (AF) by shortening of the atrial action potential duration (APD). APD-prolonging K+ channel blockers are an effective therapeutic option in AF. In vitro, the dominant negative Kv4.2W362F mutation (Kv4DN) eliminates Ito,f in murine atrial myocytes and markedly prolongs the APD, so whether this loss-of-function of Ito,f alters the atrial effective refractory period (AERP) in vivo and/or affects AF-inducibility was investigated in the present study. Methods and Results: Transvenous electrophysiological studies were performed in vivo in Kv4DN and wild-type littermate control (LMC) mice. Intriguingly, no difference was found between Kv4DN and LMC for the AERP in vivo either at baseline or after carbachol. Consequently, AF-inducibility at baseline (Kv4DN: 10/16 vs LMC: 7/13) and after carbachol (Kv4DN: 9/16 vs LMC: 6/13) did not differ between groups. However, AF-inducibility was associated with a significantly shorter AERP (inducible 51.1 ±1.4 vs non-inducible 58.4 ±1.6; P<0.01) irrespective of genotype. Conclusions: The loss-of-function of Ito,f prolongs the APD in mouse atrial myocytes in vitro, but this effect on single cells does not translate into measurable AERP prolongation in vivo and hence does not exert an anti-arrhythmic effect. However, the susceptibility of mice to AF in vivo is determined by the individual AERP, irrespective of genotype. (Circ J 2009; 73: 461 - 467)
